Table 6.
Summary of participants with single or multiple injection-site reactions excluding pain among pooled galcanezumab-treated participants in Study CGAJ and REGAIN (galcanezumab exposure analysis set)
| Injection-site reactions, n (%) | |||
|---|---|---|---|
| Total doses received (N = 1326) | 1 to 3 | 4 to 9 | > 10 |
| 1 (26) | 2 (7.7) | 0 | 0 |
| 2 (36) | 2 (5.6) | 0 | 0 |
| 3 (32) | 1 (3.1) | 1 (3.1) | 0 |
| 4 (35) | 6 (17.1) | 0 | 0 |
| 5 (32) | 6 (18.8) | 0 | 0 |
| 6 (39) | 5 (12.8) | 3 (7.7) | 0 |
| 7 (29) | 7 (24.1) | 2 (6.9) | 0 |
| 8 (26) | 7 (26.9) | 0 | 0 |
| 9a (433) | 30 (6.9) | 12 (2.8) | 2 (0.5) |
| 10 (9) | 3 (33.3) | 1 (11.1) | 0 |
| 11 (11) | 2 (18.2) | 0 | 0 |
| 12 (618) | 97 (15.7) | 34 (5.5) | 6 (1.0) |
athe number of patients receiving up to nine doses of galcanezumab, includes patients from both Study CGAJ (Month 0 to Month 12) and REGAIN (galcanezumab, Month 0 to Month 12; and placebo patients who had received placebo treatment from Month 0 to Month 3 and then initiated galcanezumab in the open-label extension phase and could receive up to nine doses of galcanezumab
Abbreviations:N number of galcanezumab-treated participants with a specific number of galcanezumab doses, n number of patients within each specific category